Any news on yervoy's patent expiration?

Yervoy, also known as ipilimumab, is a medication used to treat melanoma. It has been on the market since March 2011 and has been a crucial treatment option for patients with advanced melanoma ([1] DrugPatentWatch.com).

According to the data available on DrugPatentWatch.com, the patent for Yervoy was set to expire in Europe in April 2020 ([2] DrugPatentWatch.com). However, it's worth noting that pharmaceutical companies often have multiple patents and exclusivities surrounding their products.

As of my cut-off knowledge date (December 2023), the patent for Yervoy in the United States has been set to expire in 2026 [3] DrugPatentWatch.com. Following patent expiration, other companies may create generic versions of the medication, increasing competition and potentially offering lower prices to patients.

However, manufacturers often continue to protect their market share through additional patents for specific formulations or delivery methods. As new information becomes available, these developments could affect the patent expiration timeline for Yervoy.

In the context of Yervoy's ongoing patent protection, patients and medical professionals should continue to monitor new developments and advancements in the treatment of melanoma.

Sources:

[1] (https://www.drugpatentwatch.com/drug/Yervoy)
[2] (https://www.drugpatentwatch.com/expiration/Yervoy)
[3] (https://www.drugpatentwatch.com/exclusivities/Yervoy)